TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must give a written, signed and dated informed consent~* Chronic atopic dermatitis present for at least 1 year before Baseline~* Moderate to severe atopic dermatitis defined as per EASI, IGA and BSA.~* Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable~* Candidate for systemic treatment~Exclusion Criteria:~* Any skin disease that would confound the diagnosis or evaluation of atopic dermatitis disease activity~* Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.~* History of hypersensitivity to any of the study drug constituents or to drugs of similar chemical classes.~* Participation in prior ZPL389 studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Placebo
- ZPL389 3mg (Type: EXPERIMENTAL): ZPL389 3 mg oral powder
- ZPL389 10 mg (Type: EXPERIMENTAL): ZPL389 10 mg oral powder
- ZPL389 30mg (Type: EXPERIMENTAL): ZPL389 30 mg oral powder
- ZPL389 50mg (Type: EXPERIMENTAL): ZPL389 50 mg oral powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Outcomes of Neonates Born to Mothers With SARS-CoV-2 Infection in Shanghai

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Neonates born to mothers with SARS-CoV-2 infections.~Exclusion Criteria:~* Parents who rejected to participate in this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 28 Days
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria (Healthy Volunteers):~* Must be eighteen (18) years of age or older.~* Must be able to provide informed consent.~Inclusion Criteria (Patients):~* Patients diagnosed with malignancies of the liver.~Exclusion Criteria (All):~* Under the age of eighteen (18) years.~* BMI exceeds the size of the bore of the MRI scanner.~* Unable or unwilling to provide informed consent.~* Contraindications, as described in the volunteer consent form, to MR or US scanning such as but not limited to accidental or implanted ferrous metal and/or implanted devices whose function can be disturbed by the main magnetic field, gradient magnetic fields, or radiofrequency energy.~* Women who are pregnant, suspect they might be pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: None): Healthy volunteers will be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan.~A substudy including patients undergoing radiotherapy for malignancies of the abdomen and pelvis. They will also be asked to complete a single imaging session that will include acquiring simultaneous 4D ultrasound and 4D MRI scan.
- Patient Group (Type: None): Patients receiving radiotherapy for malignancies of the abdomen and pelvis will be asked to complete two research visits lasting approximately one hour. Each visit will include a 30 minute combined 4D ultrasound and 4D MRI scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: SPY Fluorescence Imaging Systems and Indocyanine Green to Determine the Percentage of Successful Critical Anatomy Recognition in Laparoscopic Cholecystectomy Surgeries.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is 18 years of age or older~* Subject is scheduled to undergo laparoscopic cholecystectomy, elective or emergent~* Subject provides informed consent and signs an approved informed consent document for the study~* Subject is willing to comply with the protocol and study visit schedule~Exclusion Criteria:~* Subject is pregnant or lactating~* Subject has a known allergy or history of adverse reaction to ICG, iodine or iodine dyes~* Subject has known history of cholangitis, pancreatitis, prior bile duct injury, coagulopathy or known pre-existing liver disease~* Subjects who, in the Investigator's opinion, have any medical condition that may make the subject a poor candidate for the investigation, interferes with the interpretation of study results, or integrity of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 68Ga-citrate PET/MR Imaging for Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* World Health Organization (WHO) grade 3 or 4 glioma planning to undergo surgery~* Age \>= 18 yrs.~* Karnofsky performance status of \>= 60~* Ability to understand a written informed consent document, and the willingness to sign it.~Cohort A:~- Positive for Phosphatase and Tensin Homolog (PTEN) deletion, confirmed by immunohistochemistry of tissue biopsy~Cohort B:~- Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy~Exclusion Criteria:~* Contraindications to Positron Emission Tomography (PET) imaging (e.g. pregnant or breast-feeding woman)~* Contraindications to magnetic resonance (MR) imaging (e.g. pacemakers, metallic implants, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Positive for PTEN deletion (Type: None): Confirmed by immunohistochemistry of tissue biopsy
- Negative for PTEN deletion (Type: None): Confirmed by immunohistochemistry of tissue biopsy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mobilization of Endothelial Progenitor Cells Induced by Atorvastatin in Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 18 and 75 years~* stable angina or silent ischemia~* documented CAD~* signed written informed consent~Exclusion Criteria:~* current or recent therapy (stop \< 3 months) with statins~* allergy to ASA or ticlopidine/clopidogrel~* myocardial infarction (\< 3 months)~* recent significant trauma or surgical interventions (\< 3 mesi)~* significant renal or hepatic diseases~* coagulative-hematological disorders~* cancer~* inflammatory diseases~* myopathy~* pregnancy (a pregnancy test will be performed in fertile women)~* severe coronary calcification, or small vessels disease (\< 2.5 mm), long lesions (\> 20 mm), ostial lesions, bifurcation lesions requesting treatment of the collateral vessel, multi-vessel disease requiring PCI before the completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin 10 mg (Type: ACTIVE_COMPARATOR): None
- Atorvastatin 80 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with RA based on ACR/EULAR 2010 criteria (score \>=6), or Patients diagnosed with AS based on the ASAS criteria. Patients with RA must have serology assessment performed and documented at the time of enrollment.~* Patient with RA active disease (DAS \> 2,6) and the introduction of a Bi-DMARD should be indicated. RA patients must have been treated with DMARD (methotrexate, leflunomide and sulfasalazine) or combination of these treatments for at least 3 months. Treatment will be pursued while on study.~or RA patients must have been previously treated with Bi-DMARD before initiation of the new Bi-DMARD treatment. The non-response of the previous Bi-DMARD treatment must be documented.~or Patients with AS with insufficiently controlled disease while under NSAID and indication for Bi-DMARD. These patients must be under NSAID for at least 3 months and under the same NSAID for at least 1 month prior to enrollment.~* ≥ 18 years old~* Karnofsky ≥ 80%~* Negative Pregnancy test for women with childbearing potential~* For women with childbearing potential, use of two reliable means of contraception (e.g., hormonal contraceptive, patch, vaginal ring, intrauterine device, associated with other barrier method of contraception such as the use of condoms) , throughout their participation in the study~* Absence of ECG anomaly~* written ICF signed~Exclusion Criteria:~* Pregnancy or lactation~* Liver impairment (ALT, AST or Bilirubin \> 2 ULN) at screening visit or baseline~* Kidney impairment (serum creatinine \> 1.5 mg/dL)~* History of congestive heart failure (NYHA III \& IV)~* History of malignant disease within 5 years~* History of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment~* Known hypersensitivity to the investigational drug or any of its components~* Participation to another clinical trial within 4 weeks before study inclusion except for patients who have participated or who are currently participating in an interventional study without any study drug administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 99mTc-rhAnnexin V-128, i.v. (Type: EXPERIMENTAL): Patients will receive 2 administrations of the 99mTc-rhAnnexin V-128 medical imaging agent: one at Day 1 and the other at Day 42.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gait Rehabilitation Post Stroke:the Long Term Effect of Two Walking Aids -Canes and TheraTogs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with hemiplegia following a first unilateral stroke~* will score at least level 3 on the Functional Ambulation Category (FAC) (able to walk unaided on even ground but requiring verbal prompts and stand-by help without body contact)~* must have been independent walkers prior to insult without walking aids~* Subjects will have a Mini Mental State score of 22 or above~Exclusion Criteria:~* orthopaedic or other neurological conditions that could limit walking ability~* no gross visuospatial or visual field deficits~* no medical contraindications to walking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TheraTogs (Type: EXPERIMENTAL): None
- Cane walking (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* First-time diagnosis of breast cancer~* Planned chemotherapy with anthracyclines and / or Trastuzumab~* Ability to give informed consent~Exclusion Criteria:~* Contra-indications for CMR study (e.g. implanted pacemaker / ICD; severe renal impairment (GFR\< 35 ml/min); severe claustrophobia)~* Previous history of non-ischemic cardiomyopathies or myocardial inflammation~* Inability to give informed consent~* Concomitant drug abuse (e.g. cocaine)~* Expected life expectancy \< 6 months

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: None): Consecutive patients with first-time diagnosis of metastatic breast cancer undergoing chemotherapy with anthracyclines and/or trastuzumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Crohn disease patients with a small intestine localisation (ileum or ileocecal)~2. Ileal or ileocecal resection in the month before inclusion (resection of all macroscopic lesions). If resection with temporary stoma, the patient may be included at the time of surgery to restore the continuity~3. Patient with low risk of recurrence according to the following criteria:~   (i) Total length of the resection(s) of the small intestine less than 100 cm (ii) Segmental colectomy leaving in place at least another colonic segment as the rectum~4. Preoperative rate of ASCA\> 70 arbitrary units (+/- 10%)~5. Informed consent signed to be involved in the study~Exclusion Criteria:~1. Pregnant women or without adequate contraception~2. Total length of the resection(s) of the small intestine more than 1 meter~3. Subtotal colic resection~4. Preoperative rate of ASCA\<63 arbitrary units (+/- 10%)~5. Known hypersensitivity to fluconazole or other azoles~6. Known liver disease or transaminase levels \>1.5 the normal rate~7. Patient with renal failure~8. Inability to read and sign the informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluconazole (Type: EXPERIMENTAL): 200mg per day for 6 months
- Placebo (Type: PLACEBO_COMPARATOR): One capsule per day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Elastography to Predict Development of SOS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children and adults, ages 1 month through 21 years who are undergoing allogenic or autologous myeloablative stem cell transplant.~Exclusion Criteria:~* Any other medical or social condition that in the opinion of the investigator would make them unsuitable to participate.~* Inability to properly image patient by ultrasound (e.g. uncooperative)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- All Patients Enrolled (Type: EXPERIMENTAL): All patients will undergo limited abdominal US with Doppler and SWE once a week upon admission for conditioning until the patient day +30 BMT or discharge, whichever comes first. Additional ultrasounds will also be performed if SOS is suspected.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: QOL Outcomes in CRS With Polyps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with Rhinosinusitis with polyps who have had appropriate treatment qualifying them for surgery and are good surgical candidates~Exclusion Criteria:~* Cystic fibrosis, Cilia disorders, other specialized forms of sinus disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Medical Optimization (Type: ACTIVE_COMPARATOR): Medical treatment and education x 4 months, re- eval at 4 months and possible cross-over to surgery
- Surgical treatment (Type: ACTIVE_COMPARATOR): Surgical treatment up front

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vitamin D Replacement in Patients With Urolithiasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 25-OHD deficiency or insufficiency (defined as serum level \<75 nmol/L).~* History of urolithiasis (Calcareous stones).~* 24-hour urinary calcium excretion \<7.5 mmol/day (normocalciuric).~* Low fracture risk (estimated by FRAX®, which was developed by WHO).~Exclusion Criteria:~* Age \< 18 years~* Renal dysfunction (Serum creatinine concentrations of \> 150 μmol/L).~* History of non-calcareous stones e.g. uric acid, cystine, or struvite stones.~* Hypercalcemia (serum ionized normalized calcium \> 1.32 mmol/L)~* Patients with secondary hypercalciuria e.g. primary hyperparathyroidism, sarcoidosis, hyperthyroidism, or active malignancy.~* Evidence of osteoporosis or intermediate/high fracture risk (estimated by FRAX).~* Patients taking drugs that could potentially affect urinary calcium excretion (vitamin D, calcium supplement, loop diuretics, steroids, or lithium).~* Evidence of liver dysfunction or other disorders that may cause non-nutritional vitamin D deficiency or abnormal bone development.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No vitamin D replacement (Type: None): The control arm will not receive vitamin D replacement, but patients in both study arms will receive care consistent with best care practices for stone disease. All patients will be evaluated by the stone clinic clinical nutritionist and full nutritional evaluation will be performed. All patients will be advised to maintain adequate hydration (\>2L/day), no-added salt diet (Na 80-100mmol/day), low protein diet (1 g/kg/day). Patients with hyperoxaluria will be advised to follow low-oxalate diet. All patients will be advised to maintain moderate calcium intake; 800-1200mg/day.
- Vitamin D3 tabs (Type: None): The active arm of randomization will receive vitamin D repletion in the form of oral vitamin D3 tablets 10 000 IU twice/ week for 8 consecutive weeks, followed by a maintenance dose of 1 000 IU daily for further 22 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 months to 22 years.~* Histological solid tumor confirmation.~* Measurable solid tumor by image or molecular techniques.~* Solid tumors that have failed to at least 2 chemotherapy protocols.~* Suitable haploidentical donor available.~* Lansky score \> 60%.~Exclusion Criteria:~* Serum bilirubin \> 3 mg/dl~* GFR \< 40 ml/min/1.73 mw~* Cardiac left ventricular ejection fraction \< 40%~* HIV+~* Pregnant~* Unfavorable psycho-social report.~* Antecedent of abandonment treatment.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- IL-15 STIMULATED NK CELLS (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues